Related Experiment Video
Updated: Jul 8, 2026
14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Updates on p53: modulation of p53 degradation as a therapeutic approach
1Department of Cell Cycle Control, Institute of Molecular and Cell Biology, 61, Biopolis Drive, 03-05 Proteos, Singapore 138673, Singapore.
British Journal of Cancer
|January 10, 2008
Abstract:
The p53 pathway is aberrant in most human tumours with over 50% expressing mutant p53 proteins. The pathway is critically controlled by protein degradation. Here, we discuss the latest developments in the search for small molecules that can modulate p53 pathway protein stability and restore p53 activity for cancer therapy.
Insights
Researchers are exploring small molecules to stabilize p53 pathway proteins. This approach aims to restore p53 activity, offering a new strategy for cancer therapy by targeting protein degradation in human tumours.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The p53 pathway is frequently disrupted in human cancers, with over 50% of tumors expressing mutant p53 proteins.
- Protein degradation is a critical regulatory mechanism within the p53 pathway.
- Aberrant p53 pathway signaling contributes significantly to tumorigenesis.
Purpose of the Study:
- To review recent advancements in identifying small molecules targeting the p53 pathway.
- To explore strategies for modulating p53 pathway protein stability.
- To discuss the potential of restoring p53 activity for cancer treatment.
Main Methods:
- Literature review of recent studies on p53 pathway modulators.
- Analysis of small molecules affecting protein stability and degradation.
- Discussion of therapeutic strategies based on p53 pathway restoration.
Main Results:
- Identification of emerging small molecules with the potential to stabilize p53 pathway proteins.
- Evidence suggesting that modulating protein degradation can reactivate p53.
- Exploration of the therapeutic window for p53-restoring agents.
Conclusions:
- Small molecules targeting protein degradation represent a promising avenue for cancer therapy.
- Restoring wild-type p53 function through stability modulation could be a viable treatment strategy.
- Further research into these novel agents is warranted for clinical application.
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:04Covalently Linked Protein Regulators
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
These groups modify specific amino acids in a protein.
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:36DNA Damage Can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
02:36DNA Damage can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...